Patent Grant
11028416
This application includes a sequence listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. This ASCII copy, created on Jun. 23, 2019, is named 2019-06-23_ZMGNP001US_seqlist.txt and is 331,410 bytes in size.
The present disclosure relates generally to the area of engineering microbes for overproduction of tyramine by fermentation.
Tyramine is known to exist in nature as the decarboxylation product of tyrosine. Often tyramine is produced in environments or processes where protein-rich materials have rotted or decayed. Tyramine is present in foods produced from fermentation of protein-rich substances such as animal milk or legumes. These processes rely on an external source of proteins containing aromatic amino acids and microbes expressing tyrosine decarboxylases.
Various embodiments contemplated herein may include, but need not be limited to, one or more of the following:
Embodiment 1: An engineered microbial cell, wherein the engineered microbial cell expresses: (a) a heterologous tyrosine decarboxylase (TYDC); and (b) the engineered microbial cell includes increased activity of one or more upstream enzyme(s) in the tyramine biosynthesis pathway, said increased activity being increased relative to a control cell.
Embodiment 2: The engineered microbial cell of embodiment 1, wherein the one or more upstream enzyme(s) includes 3-deoxy-D-arabino-heptulosonate-7-phosphate (DAHP) synthase.
Embodiment 3: An engineered microbial cell, wherein the engineered microbial cell expresses: (a) a heterologous tyrosine decarboxylase (TYDC); and (b) the engineered microbial cell includes increased activity of one or more enzyme(s) selected from the group consisting of a dehydroquinate synthase, a dehydroquinate dehydratase, a shikimate dehydrogenase, a shikimate kinase, EPSP synthase, aromatic pentafunctional enzyme, a chorismate synthase, a chorismate mutase, a prephenate dehydratase, a phenyalananine aminotransferase, a prephenate dehydrogenase, a prephenate aminotransferase, an arogenate dehydrogenase, a phenylalanine hydroxylase, and a tyrosine aminotransferase, said increased activity being increased relative to a control cell; wherein the engineered microbial cell produces tyramine.
Embodiment 4: The engineered microbial cell of embodiment 3, wherein the engineered microbial cell additionally expresses: (c) a feedback-disregulated 3-deoxy-D-arabino-heptulosonate-7-phosphate (DAHP) synthase or a feedback-disregulated chorismate mutase.
Embodiment 5: An engineered microbial cell, wherein the engineered microbial cell includes: (a) means for expressing a heterologous tyrosine decarboxylase (TYDC); and (b) means for increasing the activity of one or more upstream enzyme(s) in the tyramine biosynthesis pathway.
Embodiment 6: The engineered microbial cell of embodiment 5, wherein the one or more upstream enzyme(s) includes 3-deoxy-D-arabino-heptulosonate-7-phosphate (DAHP) synthase.
Embodiment 7: An engineered microbial cell, wherein the engineered microbial cell includes: (a) means for expressing a heterologous tyrosine decarboxylase (TYDC); and (b) means for increasing the activity of one or more enzyme(s) selected from the group consisting of a dehydroquinate synthase, a dehydroquinate dehydratase, a shikimate dehydrogenase, a shikimate kinase, EPSP synthase, aromatic pentafunctional enzyme, a chorismate synthase, a chorismate mutase, a prephenate dehydratase, a prephenate aminotransferase, an arogenate dehydrogenase, a phenylalanine hydroxylase, a phenyalananine aminotransferase, a prephenate dehydrogenase, and a tyrosine aminotransferase, said increased activity being increased relative to a control cell; wherein the engineered microbial cell produces tyramine.
Embodiment 8: The engineered microbial cell of embodiment 7, wherein the engineered microbial cell additionally expresses: (c) means for expressing a feedback-disregulated DAHP synthase or a feedback-disregulated chorismate mutase.
Embodiment 9: The engineered microbial cell of any one of embodiments 1-8, wherein the engineered microbial cell produces tyramine by fermentation of a substrate, wherein at least 50% of the substrate is not derived from protein or amino acid sources.
Embodiment 10: The engineered microbial cell of any one of embodiments 4, 8, or 9, wherein the engineered microbial cell includes: (a) a heterologous TYDC; and (b) a feedback-disregulated DAHP synthase.
Embodiment 11: The engineered microbial cell of any one of embodiments 3-10, wherein the engineered microbial cell includes a fungal cell.
Embodiment 12: The engineered microbial cell of any one of embodiments 3-11, wherein the engineered microbial cell includes a yeast cell.
Embodiment 13: The engineered microbial cell of embodiment 8, wherein the yeast cell includes a cell of the genus Saccharomyces.
Embodiment 14: The engineered microbial cell of embodiment 13, wherein the yeast cell is a cell of the species cerevisiae.
Embodiment 15: The engineered microbial cell of any one of embodiments 4, 8, or 9-14, wherein the DAHP synthase is a variant of a S. cerevisiae DAHP synthase.
Embodiment 16: The engineered microbial cell of any one of embodiments 3-15, wherein the heterologous TYDC includes a TYDC having at least 70% amino acid sequence identity with a TYDC from Papaver somniferum.
Embodiment 17: The engineered microbial cell of any one of embodiments 4, 8, or 9-16, wherein the: (a) heterologous TYDC includes a P. somniferum Tyrosine/DOPA decarboxylase 2; and the (b) feedback-disregulated DAHP synthase is a S. cerevisiae DAHP synthase encoded by the Aro4 gene that additionally includes a K229L mutation.
Embodiment 18: The engineered microbial cell of any one of embodiments 3-17, wherein the engineered microbial cell includes increased activity of a prephenate dehydrogenase relative to the control cell.
Embodiment 19: The engineered microbial cell of embodiment 18, wherein the engineered microbial cell expresses an extra copy of a wild-type S. cerevisiae prephenate dehydrogenase gene.
Embodiment 20: The engineered microbial cell of embodiment 18, wherein the engineered microbial cell expresses an extra copy of a wild-type S. cerevisiae transaldolase gene.
Embodiment 21: The engineered microbial cell of embodiment 2 or embodiment 6, wherein the engineered microbial cell includes a yeast cell.
Embodiment 22: The engineered microbial cell of embodiment 21, wherein the yeast cell includes a cell of the genus Yarrowia.
Embodiment 23: The engineered microbial cell of embodiment 22, wherein the yeast cell is a cell of the species lipolytica.
Embodiment 24: The engineered microbial cell of embodiment 22 or embodiment 23, wherein the heterologous TYDC includes a TYDC having at least 70% amino acid sequence identity with a TYDC from Enterococcus faecium.
Embodiment 25: The engineered microbial cell of any one of embodiments 22-24, wherein the DAHP synthase includes a DAHP synthase having at least 70% amino acid sequence identity with a DAHP synthase from S. cerevisiae.
Embodiment 26: The engineered microbial cell of embodiment 25, wherein the: (a) heterologous TYDC includes a pyridoxal-dependent decarboxylase (TYDC) from E. faecium Com15; and (b) DAHP synthase includes a phospho-2-dehydro-3-deoxyheptonate aldolase (DAHP synthase) from S. cerevisiae S288c.
Embodiment 27: An engineered microbial cell which is a yeast cell including a heterologous tyrosine decarboxylase (TYDC) having at least 70% amino acid sequence identity to a TYDC from Papaver somniferum, wherein the engineered yeast cell produces tyramine.
Embodiment 28: The engineered microbial cell of embodiment 27, wherein the engineered yeast cell is a cell of the genus Saccharomyces.
Embodiment 29: The engineered microbial cell of embodiment 28, wherein the engineered yeast cell is a cell of the species cerevisiae.
Embodiment 30: The engineered microbial cell of any one of embodiments 3-10, wherein the engineered microbial cell is a bacterial cell.
Embodiment 31: The engineered microbial cell of embodiment 30, wherein the bacterial cell is a cell of the genus Corynebacteria.
Embodiment 32: The engineered microbial cell of embodiment 31, wherein the bacterial cell is a cell of the species glutamicum.
Embodiment 33: The engineered microbial cell of any one of embodiments 30-32, wherein the bacterial cell includes a feedback-disregulated DAHP synthase that is a variant of an S. cerevisiae DAHP synthase.
Embodiment 34: The engineered microbial cell of any one of embodiments 30-33, wherein the heterologous TYDC includes a TYDC having at least 70% amino acid sequence identity with a TYDC from Enterococcus faecium or having at least 70% amino acid sequence identity with a TYDC from Zygosaccharomyces bailii.
Embodiment 35: The engineered microbial cell of embodiment 33 or embodiment 34, wherein the: (a) heterologous TYDC includes an E. faecium TYDC; and the (b) feedback-disregulated DAHP synthase is a S. cerevisiae DAHP synthase encoded by the Aro4 gene that additionally includes a K229L mutation.
Embodiment 36: The engineered microbial cell of embodiment 33 or embodiment 34, wherein the: (a) heterologous TYDC includes an Z. bailii TYDC; and the (b) feedback-disregulated DAHP synthase is a S. cerevisiae DAHP synthase encoded by the Aro4 gene that additionally includes a K229L mutation.
Embodiment 37: The engineered microbial cell of embodiment 34, additionally including increased activity of chorismate synthase or prephrenate dehydrogenase, relative to a control cell.
Embodiment 38: The engineered microbial cell of embodiment 37, wherein the engineered microbial cell includes increased activity of chorismate synthase and expresses a heterologous chorismate synthase.
Embodiment 39: The engineered microbial cell of embodiment 38, wherein the heterologous chorismate synthase includes a chorismate synthase having at least 70% amino acid sequence identity to a S. cerevisiae chorismate synthase.
Embodiment 40: The engineered microbial cell of embodiment 39, wherein the heterologous chorismate synthase includes a S. cerevisiae chorismate synthase.
Embodiment 41: The engineered microbial cell of embodiment 37, wherein the engineered microbial cell includes increased activity of prephenate dehydrogenase and expresses an additional copy of a prephenate dehydrogenase gene.
Embodiment 42: The engineered microbial cell of embodiment 41, wherein the additional copy of the prephenate dehydrogenase gene encodes a prephenate dehydrogenase having at least 70% amino acid sequence identity to a prephenate dehydrogenase from S. cerevisiae.
Embodiment 43: The engineered microbial cell of embodiment 42, wherein the additional copy of the prephenate dehydrogenase gene encodes a prephenate dehydrogenase from S. cerevisiae.
Embodiment 44: The engineered microbial cell of embodiment 2 or embodiment 6, wherein the engineered microbial cell includes a bacterial cell.
Embodiment 45: The engineered microbial cell of embodiment 44, wherein the bacterial cell includes a cell of the genus Corynebacterium or Bacillus.
Embodiment 46: The engineered microbial cell of embodiment 45, wherein the bacterial cell is a cell of the species glutamicum or subtilis, respectively.
Embodiment 47: The engineered microbial cell of embodiment 45 or embodiment 46, wherein the heterologous TYDC includes a TYDC having at least 70% amino acid sequence identity with a TYDC from Enterococcus faecium.
Embodiment 48: The engineered microbial cell of any one of embodiments 45-47, wherein the DAHP synthase includes a DAHP synthase having at least 70% amino acid sequence identity with a DAHP synthase from S. cerevisiae.
Embodiment 49: The engineered microbial cell of any one of embodiments 45-48, wherein the engineered microbial cell includes increased activity of a shikimate kinase relative to a control cell.
Embodiment 50: The engineered microbial cell of embodiment 49, wherein the shikimate kinase includes a shikimate kinase having at least 70% amino acid sequence identity with a shikimate kinase from Escherichia coli.
Embodiment 51: The engineered microbial cell of embodiment 50, wherein the: (a) heterologous TYDC includes a pyridoxal-dependent decarboxylase (TYDC) from E. faecium Com15; (b) DAHP synthase includes a phospho-2-dehydro-3-deoxyheptonate aldolase (DAHP synthase) from S. cerevisiae S288c; and (c) shikimate kinase includes a shikimate kinase from E. coli K12.
Embodiment 52: The engineered microbial cell of any one of embodiments 13-43, wherein, when cultured, the engineered microbial cell produces tyramine at a level greater than 100 mg/L of culture medium.
Embodiment 53: The engineered microbial cell of embodiment 52, wherein the engineered microbial cell produces tyramine at a level of at least 2.5 g/L of culture medium.
Embodiment 54: An engineered microbial cell which is a bacterial cell including a heterologous tyrosine decarboxylase (TYDC) having at least 70% amino acid sequence identity with a TYDC from Enterococcus faecium, wherein the engineered bacterial cell produces tyramine.
Embodiment 55: The engineered microbial cell of embodiment 54, wherein the bacterial cell is of the genus Corynebacteria.
Embodiment 56: The engineered microbial cell of embodiment 55, wherein the bacterial cell is of the species glutamicum.
Embodiment 57: An engineered microbial cell which is a bacterial cell including a heterologous tyrosine decarboxylase (TYDC) having at least 70% amino acid sequence identity with a TYDC from Zygosaccharomyces bailii, wherein the engineered bacterial cell produces tyramine.
Embodiment 58: The engineered microbial cell of embodiment 57, wherein the bacterial cell is of the genus Corynebacteria.
Embodiment 59: The engineered microbial cell of embodiment 58, wherein the bacterial cell is of the species glutamicum.
Embodiment 60: A culture of engineered microbial cells according to any one of embodiments 13-59.
Embodiment 61: The culture of embodiment 60, wherein the tyramine is produced from fermentation of a substrate wherein at least 50% of the substrate is not derived from protein or amino acid sources.
Embodiment 62: The culture of embodiment 61, wherein the substrate includes a carbon source and a nitrogen source selected from the group consisting of urea, an ammonium salt, ammonia, and any combination thereof.
Embodiment 63: The culture of any one of embodiments 60-62, wherein the engineered microbial cells are present in a concentration such that the culture has an optical density at 600 nm of 10-500.
Embodiment 64: The culture of any one of embodiments 60-63, wherein the culture includes tyramine.
Embodiment 65: The culture of any one of embodiments 60-64, wherein the culture includes tyramine at a level greater than 100 mg/L of culture medium.
Embodiment 66: The culture of any one of embodiments 60-65, wherein the culture includes tyramine at a level of at least 2.5 g/L of culture medium.
Embodiment 67: A method of culturing engineered microbial cells according to any one of embodiments 1-59, the method including culturing the cells in the presence of a fermentation substrate including a non-protein carbon and a non-protein nitrogen source, wherein the engineered microbial cells produce tyramine.
Embodiment 68: The method of embodiment 67, wherein the method includes fed-batch culture, with an initial glucose level in the range of 1-100 g/L, followed controlled sugar feeding.
Embodiment 69: The method of embodiment 67 or embodiment 68, wherein the fermentation substrate includes glucose and a nitrogen source selected from the group consisting of urea, an ammonium salt, ammonia, and any combination thereof.
Embodiment 70: The method of any one of embodiments 67-69, wherein the culture is pH-controlled during culturing.
Embodiment 71: The method of any one of embodiments 67-70, wherein the culture is aerated during culturing.
Embodiment 72: The method of any one of embodiments 67-71, wherein the engineered microbial cells produce tyramine at a level greater than 100 mg/L of culture medium.
Embodiment 73: The method of any one of embodiments 67-72, wherein the engineered microbial cells produce tyramine at a level of at least 2.5 g/L of culture medium.
Embodiment 74: The method of any one of embodiments 67-73, wherein the method additionally includes recovering tyramine from the culture.
The present disclosure describes the engineering of microbial cells for fermentative production of tyramine and provides novel engineered microbial cells and cultures, as well as related tyramine production methods.
Terms used in the claims and specification are defined as set forth below unless otherwise specified.
The term “fermentation” is used herein to refer to a process whereby a microbial cell converts one or more substrate(s) into a desired product (such as tyramine) by means of one or more biological conversion steps, without the need for any chemical conversion step.
The term “engineered” is used herein, with reference to a cell, to indicate that the cell contains at least one targeted genetic alteration introduced by man that distinguishes the engineered cell from the naturally occurring cell.
The term “endogenous” is used herein to refer to a cellular component, such as a polynucleotide or polypeptide, that is naturally present in a particular cell.
The term “heterologous” is used herein, with reference to a polynucleotide or polypeptide introduced into a host cell, to refer to a polynucleotide or polypeptide, respectively, derived from a different organism, species, or strain than that of the host cell. A heterologous polynucleotide or polypeptide has a sequence that is different from any sequence(s) found in the same host cell.
As used with reference to polypeptides, the term “wild-type” refers to any polypeptide having an amino acid sequence present in a polypeptide from a naturally occurring organism, regardless of the source of the molecule; i.e., the term “wild-type” refers to sequence characteristics, regardless of whether the molecule is purified from a natural source; expressed recombinantly, followed by purification; or synthesized. The term wild-type is also used to denote naturally occurring cells.
A “control cell” is a cell that is otherwise identical to an engineered cell being tested, including being of the same genus and species as the engineered cell, but lacks the specific genetic modification(s) being tested for in the engineered cell.
Enzymes are identified herein by the reactions they catalyze and, unless otherwise indicated, refer to any polypeptide capable of catalyzing the identified reaction. Unless otherwise indicated, enzymes may be derived from any organism and may have a naturally occurring or mutated amino acid sequence. As is well known, enzymes may have multiple functions and/or multiple names, sometimes depending on the source organism from which they derive. The enzyme names used herein encompass orthologs, including enzymes that may have one or more additional functions or a different name.
The term “feedback-disregulated” is used herein with reference to an enzyme that is normally negatively regulated by a downstream product of the enzymatic pathway (i.e., feedback-inhibition) in a particular cell. In this context, a “feedback-disregulated” enzyme is a form of the enzyme that is less sensitive to feedback-inhibition than the wild-type enzyme endogenous to the cell. A feedback-disregulated enzyme may be produced by introducing one or more mutations into a wild-type enzyme. Alternatively, a feedback-disregulated enzyme may simply be a heterologous, wild-type enzyme that, when introduced into a particular microbial cell, is not as sensitive to feedback-inhibition as the endogenous, wild-type enzyme. In some embodiments, the feedback-disregulated enzyme shows no feedback-inhibition in the microbial cell.
The term “tyramine” refers to 4-(2-aminoethyl)phenol (CAS #51-67-2).
The term “sequence identity,” in the context of two or more amino acid or nucleotide sequences, refers to two or more sequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same, when compared and aligned for maximum correspondence, as measured using a sequence comparison algorithm or by visual inspection.
For sequence comparison to determine percent nucleotide or amino acid sequence identity, typically one sequence acts as a “reference sequence,” to which a “test” sequence is compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence relative to the reference sequence, based on the designated program parameters. Alignment of sequences for comparison can be conducted using BLAST set to default parameters.
The term “titer,” as used herein, refers to the mass of a product (e.g., tyramine) produced by a culture of microbial cells divided by the culture volume.
As used herein with respect to recovering tyramine from a cell culture, “recovering” refers to separating the tyramine from at least one other component of the cell culture medium.
Tyramine is derived from the aromatic branch of amino acid biosynthesis, based on the precursors phosphoenolpyruvate (PEP) and erythrose-4-phosphate (E4P). This pathway is illustrated in
Any TYDC that is active in the microbial cell being engineered may be introduced into the cell, typically by introducing and expressing the gene encoding the enzyme using standard genetic engineering techniques. Suitable TYDCs may be derived from any source, including plant, archaeal, fungal, gram-positive bacterial, and gram-negative bacterial sources. Exemplary sources include, but are not limited to: Papaver somniferum, Petroselinum crispum, Oryza sativa, Methanosphaerula palustris Methanocaldococcus jannaschii, Zygosaccharomyces bailii, Penicillium marneffei, Talaromyces stipitatus, Trichophyton equinum, Propionibacterium sp. oral, Enterococcus faecium, Streptomyces hygroscopicus, Streptomyces sviceus, Modestobacter marinus, Pseudomonas putida, Sinorhizobium fredii. Some sources, such as P. somniferum, may include more than one form of TYDC, and any of these can be used in the methods described herein.
One or more copies of a TYDC can be introduced into a selected microbial host cell. If more than one copy of a TYDC gene is introduced, the copies can be copies of the same or different TYDC gene. In some embodiments, the heterologous TYDC gene(s) is/are expressed from a strong, constitutive promoter. In some embodiments, the heterologous TYDC gene(s) is/are expressed from inducible promoters. The heterologous genes can optionally be codon-optimized to enhance expression in the selected microbial host cell. Codon-optimization tables are available for common microbial host cells. The codon-optimization tables used in the Examples are as follows: Bacillus subtilis Kazusa codon table: www.kazusa.or.jp/codon/cgi-bin/showcodon.cgi?species=1423&aa=1&style=N; Yarrowia lipolytica Kazusa codon table: www.kazusa.or.jp/codon/cgi-bin/showcodon.cgi?species=4952&aa=1&style=N; Corynebacteria glutamicum Kazusa codon table: www.kazusa.or.jp/codon/cgi-bin/showcodon.cgi?species=340322&aa=1&style=N; Saccharomyces cerevisiae Kazusa codon table: http://www.kazusa.or.jp/codon/cgi-bin/showcodon.cgi?species=4932&aa=1&style=N. Also used, was a modified, combined codon usage scheme for S. cereviae and C. glutamicum, which is reproduced below.
In Example 1, C. glutamicum was engineered to express a TYDC from E. faecium (SEQ ID NO:1), which yielded a tyramine titer of 80 μg/L.
One approach to increasing tyramine production in a microbial cell which expresses a heterologous TYDC is to increase the activity of one or more upstream enzymes in the tyramine biosynthesis pathway. Upstream pathway enzymes include all enzymes involved in the conversions from a feedstock all the way to tyrosine. In certain embodiments, the upstream pathway enzymes refer specifically to the enzymes involved in the conversion of key precursors (i.e., E4P and PEP) into the last native metabolite (i.e. tyrosine) in the pathway leading to tyramine. In some embodiments, the activity of one or more upstream pathway enzymes is increased by modulating the expression or activity of the endogenous enzyme(s). In some embodiments, the activity of one or more upstream pathway enzymes is supplemented by introducing one or more of the corresponding genes into the TYDC-expressing microbial host cell. Such genes include those encoding a dehydroquinate synthase, a dehydroquinate dehydratase, a shikimate dehydrogenase, a shikimate kinase, EPSP synthase, aromatic pentafunctional enzyme, a chorismate synthase, a chorismate mutase, a prephenate dehydratase, a phenyalanine aminotransferase, a prephenate dehydrogenase, a prephenate aminotransferase, an arogenate dehydrogenase, a phenylalanine hydroxylase, an aromatic amino acid transferase such as a tyrosine aminotransferase, a glyceraldehyde-3-phosphate dehydrogenase, a transaldolase, a transketolase, a DAHP synthase, a phosphoenolpyruvate synthase, a glutamate synthase. Suitable upstream pathway genes may be derived from any source, including, for example, those discussed above as sources for a heterologous TYDC gene.
Example 1 describes the successful engineering of a microbial host cell to express a heterologous TYDC, along with an introduced gene encoding an upstream gene; either a chorismate synthase or a prephenate dehydrogenase. In particular, S. cerevisiae was engineered to express a TYDC from P. somniferum (SEQ ID NO:2) and an additional copy of the S. cerevisiae gene encoding either chorismate synthase (SEQ ID NO:3) or prephenate dehydrogenase (SEQ ID NO:4). The results are provided in Example 1, below.
An introduced upstream pathway gene may be heterologous or may simply be an additional copy of an endogenous gene. In some embodiments, one or more such genes are introduced into the TYDC-expressing microbial host cell and expressed from a strong constitutive promoter and/or can optionally be codon-optimized to enhance expression in the selected microbial host cell. A TYDC-expressing microbial cell can, for example, be engineered to express one or more copies of one or more upstream pathway genes.
In various embodiments, the engineering of a TYDC-expressing microbial cell to increase the activity of one or more upstream pathway enzymes increases the tyramine titer by at least 10, 20, 30, 40, 50, 60, 70, 80, or 90 percent or by at least 2-fold, 2.5-fold, 3-fold, 3.5-fold, 4-fold, 4.5-fold, 5-fold, 5.5-fold, 6-fold, 6.5-fold, 7-fold, 7.5-fold, 8-fold, 8.5-fold, 9-fold, 9.5-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, 20-fold, 21-fold, 22-fold, 23-fold, 24-fold, 25-fold, 30-fold, 35-fold, 40-fold, 45-fold, 50-fold, 55-fold, 60-fold, 65-fold, 70-fold, 75-fold, 80-fold, 85-fold, 90-fold, 95-fold, or 100-fold. In various embodiments, the increase in tyramine titer is in the range of 10 percent to 100-fold, 2-fold to 50-fold, 5-fold to 40-fold, 10-fold to 30-fold, or any range bounded by any of the values listed above. (Ranges herein include their endpoints.) These increases are determined relative to the tyramine titer observed in a tyramine-producing microbial cell that lacks any increase in activity of upstream pathway enzymes. This reference cell may have one or more other genetic alterations aimed at increasing tyramine production, e.g., the cell may express a feedback-disregulated enzyme.
In various embodiments, the tyramine titers achieved by increasing the activity of one or more upstream pathway genes are at least 10, 50, 75, 100, 200, 300, 400, 500, 600, 700, 800, or 900 mg/L or at least 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, or 10 gm/L. In various embodiments, the titer is in the range of 10 mg/L to 10 gm/L, 100 mg/L to 5 gm/L, 200 mg/L to 4 gm/L, 300 mg/L to 3 gm/L, or any range bounded by any of the values listed above.
Since aromatic amino acid biosynthesis is subject to feedback inhibition, another approach to increasing tyramine production in a microbial cell engineered to express a heterologous TYDC is to introduce feedback-disregulated forms of one or more enzymes that are normally subject to feedback inhibition in the TYDC-expressing microbial cell. Examples of such enzymes include DAHP synthase and chorismate mutase. A feedback-disregulated form can be a heterologous, wild-type enzyme that is less sensitive to feedback inhibition than the endogenous enzyme in the particular microbial host cell. Alternatively, a feedback-disregulated form can be a variant of an endogenous or heterologous enzyme that has one or more mutations rendering it less sensitive to feedback inhibition than the corresponding wild-type enzyme. Examples of the latter include variant DAHP synthases (two from S. cerevisiae, one from E. coli) that have known point mutations rendering them resistant to feedback inhibition, e.g., S. cerevisiae ARO4Q166K (SEQ ID NO:5), S. cerevisiae ARO4K229L (SEQ ID NO:6), and E. coli AroGD146N (SEQ ID NO:7). The last 5 characters of these designations indicate amino acid substitutions, using the standard one-letter code for amino acids, with the first letter referring to the wild-type residue and the last letter referring to the replacement reside; the numbers indicate the position of the amino acid substitution in the translated protein.
Example 1 describes the successful engineering of a fungal and bacterial host cells to express a heterologous TYDC, along with an introduced gene encoding a feedback-disregulated DAHP synthase. In particular, S. cerevisiae was engineered to express a TYDC 2 from P. somniferum (SEQ ID NO:2) and S. cerevisiae ARO4K229L (SEQ ID NO:6), which gave a tyramine titer of 387 μg/L.
In various embodiments, the engineering of a TYDC-expressing microbial cell to express a feedback-disregulated enzymes increases the tyramine titer by at least 10, 20, 30, 40, 50, 60, 70, 80, or 90 percent or by at least 2-fold, 2.5-fold, 3-fold, 3.5-fold, 4-fold, 4.5-fold, 5-fold, 5.5-fold, 6-fold, 6.5-fold, 7-fold, 7.5-fold, 8-fold, 8.5-fold, 9-fold, 9.5-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, 20-fold, 21-fold, 22-fold, 23-fold, 24-fold, 25-fold, 30-fold, 35-fold, 40-fold, 45-fold, 50-fold, 55-fold, 60-fold, 65-fold, 70-fold, 75-fold, 80-fold, 85-fold, 90-fold, 95-fold, or 100-fold. In various embodiments, the increase in tyramine titer is in the range of 10 percent to 100-fold, 2-fold to 50-fold, 5-fold to 40-fold, 10-fold to 30-fold, or any range bounded by any of the values listed above. These increases are determined relative to the tyramine titer observed in a tyramine-producing microbial cell that does not express a feedback-disregulated enzyme. This reference cell may (but need not) have other genetic alterations aimed at increasing tyramine production, i.e., the cell may have increased activity of an upstream pathway enzyme resulting from some means other than feedback-insensitivity.
In various embodiments, the tyramine titers achieved by using a feedback-disregulated enzyme to increase flux though the tyramine biosynthetic pathway are at least 50, 75, 100, 200, 300, 400, 500, 600, 700, 800, or 900 mg/L or at least 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, or 5 gm/L. In various embodiments, the titer is in the range of 100 mg/L to 5 gm/L, 200 mg/L to 4 gm/L, 300 mg/L to 3 gm/L, or any range bounded by any of the values listed above.
The approaches of supplementing the activity of one or more endogenous enzymes and/or introducing one or more feedback-disregulated enzymes can be combined in TYDC-expressing microbial cells to achieve even higher tyramine production levels.
Any microbe that can be used to express introduced genes can be engineered for fermentative production of tyramine as described above. In certain embodiments, the microbe is one that is naturally incapable of fermentative production of tyramine. In some embodiments, the microbe is one that is readily cultured, such as, for example, a microbe known to be useful as a host cell in fermentative production of compounds of interest. Bacteria cells, including gram positive or gram negative bacteria can be engineered as described above. Examples include, in addition to C. glutamicum cells, P. citrea, B. subtilis, B. licheniformis, B. lentus, B. brevis, B. stearothermophilus, B. alkalophilus, B. amyloliquefaciens, B. clausii, B. halodurans, B. megaterium, B. coagulans, B. circulans, B. lautus, B. thuringiensis, S. albus, S. lividans, S. coelicolor, S. griseus, Pseudomonas sp., P. alcaligenes, Lactobacilis spp. (such as L. lactis, L. plantarum), L. grayi, E. coli, E. faecium, E. gallinarum, E. casseliflavus, and/or E. faecalis cells.
There are numerous types of anaerobic cells that can be used as microbial host cells in the methods described herein. In some embodiments, the microbial cells are obligate anaerobic cells. Obligate anaerobes typically do not grow well, if at all, in conditions where oxygen is present. It is to be understood that a small amount of oxygen may be present, that is, there is some level of tolerance level that obligate anaerobes have for a low level of oxygen. Obligate anaerobes engineered as described above can be grown under substantially oxygen-free conditions, wherein the amount of oxygen present is not harmful to the growth, maintenance, and/or fermentation of the anaerobes.
Alternatively, the microbial host cells used in the methods described herein can be facultative anaerobic cells. Facultative anaerobes can generate cellular ATP by aerobic respiration (e.g., utilization of the TCA cycle) if oxygen is present. However, facultative anaerobes can also grow in the absence of oxygen. Facultative anaerobes engineered as described above can be grown under substantially oxygen-free conditions, wherein the amount of oxygen present is not harmful to the growth, maintenance, and/or fermentation of the anaerobes, or can be alternatively grown in the presence of greater amounts of oxygen.
In some embodiments, the microbial host cells used in the methods described herein are filamentous fungal cells. (See, e.g., Berka & Barnett, Biotechnology Advances, (1989), 7(2):127-154). Examples include Trichoderma longibrachiatum, T. viride, T. koningii, T. harzianum, Penicillium sp., Humicola insolens, H. lanuginose, H. grisea, Chrysosporium sp., C. lucknowense, Gliocladium sp., Aspergillus sp. (such as A. oryzae, A. niger, A. sojae, A. japonicus, A. nidulans, or A. awamori), Fusarium sp. (such as F. roseum, F. graminum F. cerealis, F. oxysporuim, or F. venenatum), Neurospora sp. (such as N. crassa or Hypocrea sp.), Mucor sp. (such as M. miehei), Rhizopus sp., and Emericella sp. cells. In particular embodiments, the fungal cell engineered as described above is A. nidulans, A. awamori, A. oryzae, A. aculeatus, A. niger, A. japonicus, T. reesei, T. viride, F. oxysporum, or F. solani. Illustrative plasmids or plasmid components for use with such hosts include those described in U.S. Patent Pub. No. 2011/0045563.
Yeasts can also be used as the microbial host cell in the methods described herein. Examples include: Saccharomyces sp., Schizosaccharomyces sp., Pichia sp., Hansenula polymorpha, Pichia stipites, Kluyveromyces marxianus, Kluyveromyces spp., Yarrowia lipolytica and Candida sp. In some embodiments, the Saccharomyces sp. is S. cerevisiae (See, e.g., Romanos et al., Yeast, (1992), 8(6):423-488). Illustrative plasmids or plasmid components for use with such hosts include those described in U.S. Pat. No. 7,659,097 and U.S. Patent Pub. No. 2011/0045563.
In some embodiments, the host cell can be an algal cell derived, e.g., from a green algae, red algae, a glaucophyte, a chlorarachniophyte, a euglenid, a chromista, or a dinoflagellate. (See, e.g., Saunders & Warmbrodt, “Gene Expression in Algae and Fungi, Including Yeast,” (1993), National Agricultural Library, Beltsville, Md.). Illustrative plasmids or plasmid components for use in algal cells include those described in U.S. Patent Pub. No. 2011/0045563.
In other embodiments, the host cell is a cyanobacterium, such as cyanobacterium classified into any of the following groups based on morphology: Chlorococcales, Pleurocapsales, Oscillatoriales, Nostocales, Synechosystic or Stigonematales (See, e.g., Lindberg et al., Metab. Eng., (2010) 12(1):70-79). Illustrative plasmids or plasmid components for use in cyanobacterial cells include those described in U.S. Patent Pub. Nos. 2010/0297749 and 2009/0282545 and in Intl. Pat. Pub. No. WO 2011/034863.
Microbial cells can be engineered for fermentative tyramine production using conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, and biochemistry, which are within the skill of the art. Such techniques are explained fully in the literature, see e.g., “Molecular Cloning: A Laboratory Manual,” fourth edition (Sambrook et al., 2012); “Oligonucleotide Synthesis” (M. J. Gait, ed., 1984); “Culture of Animal Cells: A Manual of Basic Technique and Specialized Applications” (R. I. Freshney, ed., 6th Edition, 2010); “Methods in Enzymology” (Academic Press, Inc.); “Current Protocols in Molecular Biology” (F. M. Ausubel et al., eds., 1987, and periodic updates); “PCR: The Polymerase Chain Reaction,” (Mullis et al., eds., 1994); Singleton et al., Dictionary of Microbiology and Molecular Biology 2nd ed., J. Wiley & Sons (New York, N.Y. 1994).
Vectors are polynucleotide vehicles used to introduce genetic material into a cell. Vectors useful in the methods described herein can be linear or circular. Vectors can integrate into a target genome of a host cell or replicate independently in a host cell. For many applications, integrating vectors that produced stable transformants are preferred. Vectors can include, for example, an origin of replication, a multiple cloning site (MCS), and/or a selectable marker. An expression vector typically includes an expression cassette containing regulatory elements that facilitate expression of a polynucleotide sequence (often a coding sequence) in a particular host cell. Vectors include, but are not limited to, integrating vectors, prokaryotic plasmids, episomes, viral vectors, cosmids, and artificial chromosomes.
Illustrative regulatory elements that may be used in expression cassettes include promoters, enhancers, internal ribosomal entry sites (IRES), and other expression control elements (e.g., transcription termination signals, such as polyadenylation signals and poly-U sequences). Such regulatory elements are described, for example, in Goeddel, Gene Expression Technology: Methods In Enzymology 185, Academic Press, San Diego, Calif. (1990).
In some embodiments, vectors may be used to introduce systems that can carry out genome editing, such as CRISPR systems. See U.S. Patent Pub. No. 2014/0068797, published 6 Mar. 2014; see also Jinek M., et al., “A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity,” Science 337:816-21, 2012). In Type II CRISPR-Cas9 systems, Cas9 is a site-directed endonuclease, namely an enzyme that is, or can be, directed to cleave a polynucleotide at a particular target sequence using two distinct endonuclease domains (HNH and RuvC/RNase H-like domains). Cas9 can be engineered to cleave DNA at any desired site because Cas9 is directed to its cleavage site by RNA. Cas9 is therefore also described as an “RNA-guided nuclease.” More specifically, Cas9 becomes associated with one or more RNA molecules, which guide Cas9 to a specific polynucleotide target based on hybridization of at least a portion of the RNA molecule(s) to a specific sequence in the target polynucleotide. Ran, F. A., et al., (“In vivo genome editing using Staphylococcus aureus Cas9,” Nature 520(7546):186-91, 2015 Apr. 9], including all extended data) present the crRNA/tracrRNA sequences and secondary structures of eight Type II CRISPR-Cas9 systems. Cas9-like synthetic proteins are also known in the art (see U.S. Published Patent Application No. 2014-0315985, published 23 Oct. 2014).
Example 1 describes two illustrative integration approaches for introducing polynucleotides into the genomes of S. cerevisiae and C. glutamicum cells.
Vectors or other polynucleotides can be introduced into microbial cells by any of a variety of standard methods, such as transformation, conjugation, electroporation, nuclear microinjection, transduction, transfection (e.g., lipofection mediated or DEAE-Dextrin mediated transfection or transfection using a recombinant phage virus), incubation with calcium phosphate DNA precipitate, high velocity bombardment with DNA-coated microprojectiles, and protoplast fusion. Transformants can be selected by any method known in the art. Suitable methods for selecting transformants are described in U.S. Patent Pub. Nos. 2009/0203102, 2010/0048964, and 2010/0003716, and International Publication Nos. WO 2009/076676, WO 2010/003007, and WO 2009/132220.
The above-described methods can be used to produce engineered microbial cells that produce, and in certain embodiments, overproduce, tyramine. Engineered microbial cells can have at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more genetic alterations, such as 30-40 alterations, as compared to a wild-type microbial cell, such as any of the microbial host cells described herein. Engineered microbial cells described in the Example below have one, two, or three genetic alterations, but those of skill in the art can, following the guidance set forth herein, design microbial cells with additional alterations. In some embodiments, the engineered microbial cells have not more than 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, or 4 genetic alterations, as compared to a wild-type microbial cell. In various embodiments, microbial cells engineered for tyramine production can have a number of genetic alterations falling within the any of the following illustrative ranges: 1-10, 1-9, 1-8, 2-7, 2-6, 2-5, 2-4, 2-3, 3-7, 3-6, 3-5, 3-4, etc.
In some embodiments, an engineered microbial cell expresses at least one heterologous tyrosine decarboxylase (TYDC). This is necessary in the case of a microbial host cell that does not naturally produce tyramine. In various embodiments, the microbial cell can include and express, for example: (1) a single heterologous TYDC gene, (2) two or more heterologous TYDC genes, which can be the same or different (in other words, multiple copies of the same heterologous TYDC genes can be introduced or multiple, different heterologous TYDC genes can be introduced), (3) a single heterologous TYDC gene and one or more additional copies of an endogenous TYDC gene, or (4) two or more heterologous TYDC genes, which can be the same or different, and one or more additional copies of an endogenous TYDC gene.
This engineered host cell can include at least one additional genetic alteration that increases flux through the pathway leading to the production of tyrosine (the immediate precursor of tyramine). These “upstream” enzymes in the pathway include: dehydroquinate synthase, dehydroquinate dehydratase, shikimate dehydrogenase, shikimate kinase, EPSP synthase, aromatic pentafunctional enzyme, chorismate synthase, chorismate mutase, prephenate dehydratase, phenyalananine aminotransferase, prephenate dehydrogenase, prephenate aminotransferase, arogenate dehydrogenase, phenylalanine hydroxylase, and tyrosine aminotransferase, including any isoforms, paralogs, or orthologs having these enzymatic activities (which as those of skill in the art readily appreciate may be known by different names). The at least one additional alteration can increase the activity of the upstream pathway enzyme(s) by any available means, e.g., by: (1) modulating the expression or activity of the endogenous enzyme(s), (2) expressing one or more additional copies of the genes for the endogenous enzymes, or (3) expressing one or more copies of the genes for one or more heterologous enzymes.
In some embodiments, increased flux through the pathway can be achieved by expressing one or more genes encoding a feedback-disregulated enzyme, as discussed above. For example, the engineered host cell can include and express: (1) one or more feedback-disregulated DAHP synthase genes, (2) one or more feedback-disregulated chorismate mutase genes, or (3) one or more feedback-disregulated DAHP synthase genes and one or more feedback-disregulated chorismate mutase genes. Thus, an engineered microbial cell having any of these genetic alterations can also include at least one heterologous TYDC and, optionally, one more genetic alterations that increase the activity of one or more upstream pathway enzymes.
The engineered microbial cells can contain introduced genes that have a wild-type nucleotide sequence or that differ from wild-type. For example, the wild-type nucleotide sequence can be codon-optimized for expression in a particular host cell. The amino acid sequences encoded by any of these introduced genes can be wild-type or can differ from wild-type. In various embodiments, the amino acid sequences have at least 0 percent, 70 percent, 75 percent, 80 percent, 85 percent, 90 percent, 95 percent or 100 percent amino acid sequence identity with a wild-type amino acid sequence.
The engineered microbial cells can, in various embodiments, be capable of producing tyramine at high titer, as described above. In some embodiments, the engineered microbial cell can produce tyramine by fermentation of a substrate, wherein at least 20 percent of the substrate is not derived from protein or amino acid sources. In various embodiments, at least 25 percent, 30 percent, 35 percent, 40 percent, 45 percent, 50 percent, 55 percent, 60 percent, 65 percent, 70 percent, 75 percent, 80 percent, 85 percent, 90 percent, 95 percent or 100 percent of the substrate is not derived from protein or amino acid sources. In some embodiments, the percentage of the fermentation substrate that is not derived from protein or amino acid sources falls within any of the following illustrative ranges: 40-100 percent, 40-90 percent, 40-80 percent, 50-100 percent, 50-90 percent, 50-80 percent, 60-100 percent, 60-90 percent, 60-80 percent, etc.
The approach described herein has been carried out in fungal cells, namely the yeast S. cerevisiae (a eukaryote), and in bacterial cells, namely C. glutamicum (a prokaryote). (See Example 1.)
In certain embodiments the engineered yeast (e.g., S. cerevisiae) cell expresses a heterologous tyrosine decarboxylase (TYDC) having at least 70 percent, 75 percent, 80 percent, 85 percent, 90 percent, 95 percent or 100 percent amino acid sequence identity to a TYDC from Papaver somniferum. In various embodiments, the P. somniferum TYDC can include SEQ ID NO:2. This may be the only genetic alteration of the engineered yeast cell, or the yeast cell can include one or more additional genetic alterations, as discussed more generally above.
In particular embodiments, the engineered yeast (e.g., S. cerevisiae) cell additionally expresses a variant of a S. cerevisiae DAHP synthase, which typically has at least 70 percent, 75 percent, 80 percent, 85 percent, 90 percent, or 95 percent amino acid sequence identity to the wild-type S. cerevisiae DAHP synthase. In an illustrative embodiment, the engineered yeast (e.g., S. cerevisiae) cell expresses a P. somniferum Tyrosine/DOPA decarboxylase 2 (SEQ ID NO:2) and a feedback-disregulated S. cerevisiae DAHP synthase encoded by the Aro4 gene that additionally comprises a K229L mutation (SEQ ID NO:6) to yield a tyramine titer of about 387 μg/L (see Table 1—First-Round Results).
An illustrative yeast (e.g., S. cerevisiae) cell having a third genetic alteration can additionally have increased activity of an upstream pathway enzyme, such as prephenate dehydrogenase, relative to the control cell, e.g., produced by introducing an additional copy of a wild-type S. cereviseae prephenate dehydrogenase (SEQ ID NO:4) gene into the cell or a gene encoding a prephenate dehydrogenase having at least 70 percent, 75 percent, 80 percent, 85 percent, 90 percent, or 95 percent amino acid sequence identity to the wild-type S. cereviseae prephenate dehydrogenase. This alteration increased the tyramine titer to about 346 mg/L (see Table 1—Second-Round Results).
An illustrative yeast (e.g., S. cerevisiae) cell having a fourth genetic alteration can additionally have increased activity of an upstream pathway enzyme, such as transaldolase, relative to the control cell, e.g., produced by introducing an additional copy of a wild-type S. cereviseae transaldolase (SEQ ID NO:8) gene into the cell or a gene encoding a transaldolase having at least 70 percent, 75 percent, 80 percent, 85 percent, 90 percent, or 95 percent amino acid sequence identity to the wild-type S. cereviseae transaldolase. This alteration gave a tyramine titer of about 299 mg/L (see Table 7—Improvement-Round Results for Saccharomyces cerevisiae Strains Engineered to Produce Tyramine; note that this was better than the control strain, which contained the three alterations described in the preceding paragraphs; the titer for the control strain, in this experiment, was about 266 mg/L). In an illustrative embodiment, an engineered S. cereviseae cell expresses versions of these genes that are codon-optimized using a using a modified combined codon table for Corynebacterium glutamicum and S. cereviseae.
In certain embodiments the engineered yeast (e.g., Yarrowia lipolytica) cell expresses a heterologous tyrosine decarboxylase (TYDC) having at least 70 percent, 75 percent, 80 percent, 85 percent, 90 percent, 95 percent or 100 percent amino acid sequence identity to a pyridoxal-dependent decarboxylase (TYDC) from Enterococcus faecium (e.g., Com15). In various embodiments, the E. faecium TYDC can include SEQ ID NO:1. This may be the only genetic alteration of the engineered yeast cell, or the yeast cell can include one or more additional genetic alterations, as discussed more generally above.
In particular embodiments, the engineered yeast (e.g., Y. lipolytica) cell additionally expresses a S. cerevisiae DAHP synthase, which typically has at least 70 percent, 75 percent, 80 percent, 85 percent, 90 percent, or 95 percent amino acid sequence identity to the wild-type S. cerevisiae (e.g., S288c) phospho-2-dehydro-3-deoxyheptonate aldolase (DAHP synthase)(SEQ ID NO:9). This additional genetic alteration yielded a tyramine titer of 55 mg/L (see Table 3—Host Evaluation Results for Yarrowia lipolytica Strains Engineered to Produce Tyramine.) In an illustrative embodiment, an engineered Y. lipolytica cell expresses versions of these genes that are codon-optimized for Y. lipolytica (SEQ ID NO:10).
In certain embodiments the engineered bacterial (e.g., C. glutamicum) cell expresses a heterologous tyrosine decarboxylase (TYDC) having at least 70 percent, 75 percent, 80 percent, 85 percent, 90 percent, 95 percent or 100 percent amino acid sequence identity to a TYDC from Enterococcus faecium (e.g., Com15) or from Zygosaccharomyces bailii. For example, the E. faecium TYDC can include SEQ ID NO:1, and the Z. bailii TYDC can include SEQ ID NO:11. Expression of a heterologous TYDC may be the only genetic alteration of the engineered bacterial cell, or the bacterial cell can include one or more additional genetic alterations, as discussed more generally above.
In particular embodiments, the engineered bacterial (e.g., C. glutamicum) cell additionally expresses a S. cerevisiae DAHP synthase (e.g., phospho-2-dehydro-3-deoxyheptonate aldolase from strain 288c) or a variant thereof, which typically has at least 70 percent, 75 percent, 80 percent, 85 percent, 90 percent, or 95 percent amino acid sequence identity to the wild-type S. cerevisiae DAHP synthase (SEQ ID NO:9). Both genes can be codon-optimized, for example, for S. cerevisiae. In illustrative embodiments, the engineered bacterial (e.g., C. glutamicum) cell expresses either (or both) an E. faecium TYDC (SEQ ID NO:1) or a Z. bailii TYDC (SEQ ID NO:11) in combination with a feedback-disregulated S. cerevisiae DAHP synthase encoded by the Aro4 gene that additionally comprises a K229L mutation (SEQ ID NO:6).
Alternatively, or in addition to expressing a DAHP synthase variant, a TYDC-expressing bacterial (e.g., C. glutamicum) cell can have increased activity of an upstream pathway enzyme, such as chorismate synthase and/or prephrenate dehydrogenase relative to the control cell. In an illustrative embodiment, the engineered bacterial (e.g., C. glutamicum) cell expresses an E. faecium TYDC (SEQ ID NO:1) in combination with a copy of a wild-type S. cereviseae chorismate synthase (SEQ ID NO:12) gene or a gene encoding a chorismate synthase having at least 70 percent, 75 percent, 80 percent, 85 percent, 90 percent, or 95 percent amino acid sequence identity to the wild-type S. cereviseae chorismate synthase (SEQ ID NO:3). In another illustrative embodiment, the engineered bacterial (e.g., C. glutamicum) cell expresses an E. faecium TYDC (SEQ ID NO:1) in combination with a copy of a wild-type S. cereviseae prephenate dehydrogenase (SEQ ID NO:13) gene or a gene encoding a prephenate dehydrogenase having at least 70 percent, 75 percent, 80 percent, 85 percent, 90 percent, or 95 percent amino acid sequence identity to the wild-type S. cereviseae prephenate dehydrogenase (SEQ ID NO:4).
An illustrative C. glutamicum strain from Example 2B produced 467 mg/L tyramine and expressed pyridoxal-dependent decarboxylase (TYDC) from E. faecium Com15 (UniProt ID C9ASN2) (SEQ ID NO:1), phospho-2-dehydro-3-deoxyheptonate aldolase from (DAHP synthase) S. cerevisiae S288c (UniProt ID P32449) (SEQ ID NO:9), where the DNA sequences for both enzymes was codon-optimized for S. cerevisiae. (Table 6,
In certain embodiments the engineered bacterial (e.g., Bacillus subtilus) cell expresses a heterologous tyrosine decarboxylase (TYDC) having at least 70 percent, 75 percent, 80 percent, 85 percent, 90 percent, 95 percent or 100 percent amino acid sequence identity to a TYDC from Enterococcus faecium (e.g., Com15). For example, the E. faecium TYDC can include SEQ ID NO:1. Expression of a heterologous TYDC may be the only genetic alteration of the engineered bacterial cell, or the bacterial cell can include one or more additional genetic alterations, as discussed more generally above.
In particular embodiments, the engineered bacterial (e.g., B. subtilus) cell additionally expresses a variant of a S. cerevisiae DAHP synthase (e.g., phospho-2-dehydro-3-deoxyheptonate aldolase from strain 288c), which typically has at least 70 percent, 75 percent, 80 percent, 85 percent, 90 percent, or 95 percent amino acid sequence identity to the wild-type S. cerevisiae DAHP synthase (SEQ ID NO:9).
An illustrative bacterial (e.g., B. subtilus) cell having a third genetic alteration can additionally have increased activity of an upstream pathway enzyme, such as shikimate kinase, relative to the control cell, e.g., produced by introducing an additional copy of a wild-type E. coli (e.g., K12) shikimate kinase 2 (SEQ ID NO:14) gene into the cell or a gene encoding a shikimate kinase having at least 70 percent, 75 percent, 80 percent, 85 percent, 90 percent, or 95 percent amino acid sequence identity to the wild-type E. coli shikimate kinase 2 (SEQ ID NO:15). In an illustrative embodiment, an engineered B. subtilus cell expresses versions of these genes that are codon-optimized for S. cerevisiae.
Any of the microbial cells described herein can be cultured, e.g., for maintenance, growth, and/or tyramine production. Generally, tyramine is produced from fermentation of a substrate wherein at least 20% of the substrate is not derived from protein or amino acid sources. Accordingly, cultures of the engineered microbial cells described herein include a fermentation substrate, wherein at least 20 percent of the substrate is not derived from protein or amino acid sources. In various embodiments, at least 25 percent, 30 percent, 35 percent, 40 percent, 45 percent, 50 percent, 55 percent, 60 percent, 65 percent, 70 percent, 75 percent, 80 percent, 85 percent, 90 percent, 95 percent or 100 percent of the substrate is not derived from protein or amino acid sources. In some embodiments, the percentage of the fermentation substrate that is not derived from protein or amino acid sources falls within any of the following illustrative ranges: 40-100 percent, 40-90 percent, 40-80 percent, 50-100 percent, 50-90 percent, 50-80 percent, 60-100 percent, 60-90 percent, 60-80 percent, etc.
In some embodiments, the cultures are grown to an optical density at 600 nm of 10-500, such as an optical density of 50-150.
In various embodiments, the cultures include produced tyramine at titers of at least 10, 50, 75, 100, 200, 300, 400, 500, 600, 700, 800, or 900 mg/L or at least 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, or 10 gm/L. In various embodiments, the titer is in the range of 10 mg/L to 10 gm/L, 100 mg/L to 5 gm/L, 200 mg/L to 4 gm/L, 300 mg/L to 3 gm/L, or any range bounded by any of the values listed above.
Microbial cells can be cultured in any suitable medium including, but not limited to, a minimal medium, i.e., one containing the minimum nutrients possible for cell growth. Minimal medium typically contains: (1) a carbon source for microbial growth; (2) salts, which may depend on the particular microbial cell and growing conditions; and (3) water. Suitable media can also include any combination of the following: a nitrogen source for growth and product formation, a sulfur source for growth, a phosphate source for growth, metal salts for growth, vitamins for growth, and other cofactors for growth.
Any suitable carbon source can be used to cultivate the host cells. The term “carbon source” refers to one or more carbon-containing compounds capable of being metabolized by a microbial cell. In various embodiments, the carbon source is a carbohydrate (such as a monosaccharide, a disaccharide, an oligosaccharide, or a polysaccharide), or an invert sugar (e.g., enzymatically treated sucrose syrup). Illustrative monosaccharides include glucose (dextrose), fructose (levulose), and galactose; illustrative oligosaccharides include dextran or glucan, and illustrative polysaccharides include starch and cellulose. Suitable sugars include C6 sugars (e.g., fructose, mannose, galactose, or glucose) and C5 sugars (e.g., xylose or arabinose). Other, less expensive carbon sources include sugar cane juice, beet juice, sorghum juice, and the like, any of which may, but need not be, fully or partially deionized.
The salts in a culture medium generally provide essential elements, such as magnesium, nitrogen, phosphorus, and sulfur to allow the cells to synthesize proteins and nucleic acids.
Minimal medium can be supplemented with one or more selective agents, such as antibiotics.
To produce tyramine, the culture medium can include, and/or is supplemented during culture with, glucose and/or a nitrogen source such as urea, an ammonium salt, ammonia, or any combination thereof.
Materials and methods suitable for the maintenance and growth of microbial cells are well known in the art. See, for example, U.S. Pub. Nos. 2009/0203102, 2010/0003716, and 2010/0048964, and International Pub. Nos. WO 2004/033646, WO 2009/076676, WO 2009/132220, and WO 2010/003007, Manual of Methods for General Bacteriology Gerhardt et al., eds), American Society for Microbiology, Washington, D.C. (1994) or Brock in Biotechnology: A Textbook of Industrial Microbiology, Second Edition (1989) Sinauer Associates, Inc., Sunderland, Mass.
In general, cells are grown and maintained at an appropriate temperature, gas mixture, and pH (such as about 20° C. to about 37° C., about 6% to about 84% CO2, and a pH between about 5 to about 9). In some aspects, cells are grown at 35° C. In certain embodiments, such as where thermophilic bacteria are used as the host cells, higher temperatures (e.g., 50° C.-75° C.) may be used. In some aspects, the pH ranges for fermentation are between about pH 5.0 to about pH 9.0 (such as about pH 6.0 to about pH 8.0 or about 6.5 to about 7.0). Cells can be grown under aerobic, anoxic, or anaerobic conditions based on the requirements of the particular cell.
Standard culture conditions and modes of fermentation, such as batch, fed-batch, or continuous fermentation that can be used are described in U.S. Publ. Nos. 2009/0203102, 2010/0003716, and 2010/0048964, and International Pub. Nos. WO 2009/076676, WO 2009/132220, and WO 2010/003007. Batch and Fed-Batch fermentations are common and well known in the art, and examples can be found in Brock, Biotechnology: A Textbook of Industrial Microbiology, Second Edition (1989) Sinauer Associates, Inc.
In some embodiments, the cells are cultured under limited sugar (e.g., glucose) conditions. In various embodiments, the amount of sugar that is added is less than or about 105% (such as about 100%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, or 10%) of the amount of sugar that can be consumed by the cells. In particular embodiments, the amount of sugar that is added to the culture medium is approximately the same as the amount of sugar that is consumed by the cells during a specific period of time. In some embodiments, the rate of cell growth is controlled by limiting the amount of added sugar such that the cells grow at the rate that can be supported by the amount of sugar in the cell medium. In some embodiments, sugar does not accumulate during the time the cells are cultured. In various embodiments, the cells are cultured under limited sugar conditions for times greater than or about 1, 2, 3, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, or 70 hours or even up to about 5-10 days. In various embodiments, the cells are cultured under limited sugar conditions for greater than or about 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 95, or 100% of the total length of time the cells are cultured. While not intending to be bound by any particular theory, it is believed that limited sugar conditions can allow more favorable regulation of the cells.
In some aspects, the cells are grown in batch culture. The cells can also be grown in fed-batch culture or in continuous culture. Additionally, the cells can be cultured in minimal medium, including, but not limited to, any of the minimal media described above. The minimal medium can be further supplemented with 1.0% (w/v) glucose (or any other six-carbon sugar) or less. Specifically, the minimal medium can be supplemented with 1% (w/v), 0.9% (w/v), 0.8% (w/v), 0.7% (w/v), 0.6% (w/v), 0.5% (w/v), 0.4% (w/v), 0.3% (w/v), 0.2% (w/v), or 0.1% (w/v) glucose. In some cultures, significantly higher levels of sugar (e.g., glucose) are used, e.g., at least 10% (w/v), 20% (w/v), 30% (w/v), 40% (w/v), 50% (w/v), 60% (w/v), 70% (w/v), or up to the solubility limit for the sugar in the medium. In some embodiments, the sugar levels falls within a range of any two of the above values, e.g.: 0.1-10% (w/v), 1.0-20% (w/v), 10-70% (w/v), 20-60% (w/v), or 30-50% (w/v). Furthermore, different sugar levels can be used for different phases of culturing. For fed-batch culture (e.g., of S. cerevisiae or C. glutamicum), the sugar level can be about 100-200 g/L (10-20% (w/v)) in the batch phase and then up to about 500-700 g/L (50-70% in the feed).
Additionally, the minimal medium can be supplemented 0.1% (w/v) or less yeast extract. Specifically, the minimal medium can be supplemented with 0.1% (w/v), 0.09% (w/v), 0.08% (w/v), 0.07% (w/v), 0.06% (w/v), 0.05% (w/v), 0.04% (w/v), 0.03% (w/v), 0.02% (w/v), or 0.01% (w/v) yeast extract. Alternatively, the minimal medium can be supplemented with 1% (w/v), 0.9% (w/v), 0.8% (w/v), 0.7% (w/v), 0.6% (w/v), 0.5% (w/v), 0.4% (w/v), 0.3% (w/v), 0.2% (w/v), or 0.1% (w/v) glucose and with 0.1% (w/v), 0.09% (w/v), 0.08% (w/v), 0.07% (w/v), 0.06% (w/v), 0.05% (w/v), 0.04% (w/v), 0.03% (w/v), or 0.02% (w/v) yeast extract. In some cultures, significantly higher levels of yeast extract can be used, e.g., at least 1.5% (w/v), 2.0% (w/v), 2.5% (w/v), or 3% (w/v). In some cultures (e.g., of S. cerevisiae or C. glutamicum), the yeast extract level falls within a range of any two of the above values, e.g.: 0.5-3.0% (w/v), 1.0-2.5% (w/v), or 1.5-2.0% (w/v).
Illustrative materials and methods suitable for the maintenance and growth of the engineered microbial cells described herein can be found below in Example 1.
Any of the methods described herein may further include a step of recovering tyramine. In some embodiments, the produced tyramine contained in a so-called harvest stream is recovered/harvested from the production vessel. The harvest stream may include, for instance, cell-free or cell-containing aqueous solution coming from the production vessel, which contains tyramine as a result of the conversion of production substrate by the resting cells in the production vessel. Cells still present in the harvest stream may be separated from the tyramine by any operations known in the art, such as for instance filtration, centrifugation, decantation, membrane crossflow ultrafiltration or microfiltration, tangential flow ultrafiltration or microfiltration or dead end filtration. After this cell separation operation, the harvest stream is essentially free of cells.
Further steps of separation and/or purification of the produced tyramine from other components contained in the harvest stream, i.e., so-called downstream processing steps may optionally be carried out. These steps may include any means known to a skilled person, such as, for instance, concentration, extraction, crystallization, precipitation, adsorption, ion exchange, chromatography, distillation, electrodialysis, bipolar membrane electrodialysis and/or reverse osmosis. Any of these procedures can be used alone or in combination to purify tyramine. Further purification steps can include one or more of, e.g., concentration, crystallization, precipitation, washing and drying, treatment with activated carbon, ion exchange and/or re-crystallization. The design of a suitable purification protocol may depend on the cells, the culture medium, the size of the culture, the production vessel, etc. and is within the level of skill in the art.
The following example is given for the purpose of illustrating various embodiments of the disclosure and is not meant to limit the present disclosure in any fashion. Changes therein and other uses which are encompassed within the spirit of the disclosure, as defined by the scope of the claims, will be identifiable to those skilled in the art.
All strains tested for this work were transformed with plasmid DNA designed using proprietary software. Plasmid designs were specific to one of the two host organisms engineered in this work. The plasmid DNA was physically constructed by a standard DNA assembly method. This plasmid DNA was then used to integrate metabolic pathway inserts by one of two host-specific methods, each described below.
A “split-marker, double-crossover” genomic integration strategy has been developed to engineer S. cerevisiae strains.
A “loop-in, single-crossover” genomic integration strategy has been developed to engineer C. glutamicum strains.
Loop-in, loop-out constructs (shown under the heading “Loop-in, loop-out) contained two 2-kb homology arms (5′ and 3′ arms), gene(s) of interest (arrows), a positive selection marker (denoted “Marker”), and a counter-selection marker. Similar to “loop-in” only constructs, a single crossover event integrated the plasmid into the chromosome of C. glutamicum. Note: only one of two possible integrations is shown here. Correct genomic integration was confirmed by colony PCR and counter-selection was applied so that the plasmid backbone and counter-selection marker could be excised. This results in one of two possibilities: reversion to wild-type (lower left box) or the desired pathway integration (lower right box). Again, correct genomic loop-out is confirmed by colony PCR. (Abbreviations: Primers: UF=upstream forward, DR=downstream reverse, IR=internal reverse, IF=internal forward.)
Separate workflows were established for C. glutamicum and S. cerevisiae due to differences in media requirements and growth. Both processes involved a hit-picking step that consolidated successfully built strains using an automated workflow that randomized strains across the plate. For each strain that was successfully built, up to four replicates were tested from distinct colonies to test colony-to-colony variation and other process variation. If fewer than four colonies were obtained, the existing colonies were replicated so that at least four wells were tested from each desired genotype.
The colonies were consolidated into 96-well plates with selective medium (BHI for C. glutamicum, SD-ura for S. cerevisiae) and cultivated for two days until saturation and then frozen with 16.6% glycerol at −80° C. for storage. The frozen glycerol stocks were then used to inoculate a seed stage in minimal media with a low level of amino acids to help with growth and recovery from freezing. The seed plates were grown at 30° C. for 1-2 days. The seed plates were then used to inoculate a main cultivation plate with minimal medium and grown for 48-88 hours. Plates were removed at the desired time points and tested for cell density (OD600), viability and glucose, supernatant samples stored for LC-MS analysis for product of interest.
Cell density was measured using a spectrophotometric assay detecting absorbance of each well at 600 nm. Robotics were used to transfer fixed amounts of culture from each cultivation plate into an assay plate, followed by mixing with 175 mM sodium phosphate (pH 7.0) to generate a 10-fold dilution. The assay plates were measured using a Tecan M1000 spectrophotometer and assay data uploaded to a LIMS database. A non-inoculated control was used to subtract background absorbance. Cell growth was monitored by inoculating multiple plates at each stage, and then sacrificing an entire plate at each time point.
To minimize settling of cells while handling large number of plates (which could result in a non-representative sample during measurement) each plate was shaken for 10-15 seconds before each read. Wide variations in cell density within a plate may also lead to absorbance measurements outside of the linear range of detection, resulting in underestimate of higher OD cultures. In general, the tested strains so far have not varied significantly enough for this be a concern.
Two methods were used to measure cell viability. The first assay utilized a single stain, propidium iodide, to assess cell viability. Propidium iodide binds to DNA and is permeable to cells with compromised cell membranes. Cells that take up the propidium iodide are considered non-viable. A dead cell control was used to normalize to total number of cells, by incubating a cell sample of control culture at 95° C. for 10 minutes. These control samples and test samples were incubated with the propidium iodide stain for 5 minutes, washed twice with 175 mM phosphate buffer, and fluorescence measured in black solid-bottom 96-well plates at 617 nm.
Glucose is measured using an enzymatic assay with 16 U/mL glucose oxidase (Sigma) with 0.2 U/mL horseradish peroxidase (Sigma) and 0.2 mM Amplex red in 175 mM sodium phosphate buffer, pH 7. Oxidation of glucose generates hydrogen peroxide, which is then oxidized to reduce Amplex red, which changes absorbance at 560 nm. The change is absorbance is correlated to the glucose concentration in the sample using standards of known concentration.
To harvest extracellular samples for analysis by LC-MS, liquid and solid phases were separated via centrifugation. Cultivation plates were centrifuged at 2000 rpm for 4 minutes, and the supernatant was transferred to destination plates using robotics. 75 μL of supernatant was transferred to each plate, with one stored at 4° C., and the second stored at 80° C. for long-term storage.
A first round of genetic engineering and screening was carried out using C. glutamicum and S. cerevisiae as host cells. A heterologous TYDC was expressed in the host cells, in some cases, along with a feedback-disregulated DAHP synthase. In some cases, the TYDC nucleotide sequence was codon-optimized for either C. glutamicum or S. cerevisiae. The strains were produced and cultured as described above, and the tyramine titer in the culture media was measured by LC-MS. The strains and results are shown in Table 1. The best-performing strain was an S. cerevisiae strain expressing a P. somniferum TYDC (SEQ ID NO:2), along with an S. cerevisiae DAHP synthase with a K229L amino acid substitution (SEQ ID NO:6), which gave a tyramine titer of almost 387 μg/L of culture medium. This strain was selected for a second round of genetic engineering and screening.
C. glutamicum
E. faecium (S.
faecium)
Z. bailii ISA1307
E. faecium (S.
S. cerevisiae***
faecium)
M. palustris
Propionibacterium
P. crispum
E. coli****
T. equinum
E. coli
S. sviceus
P. putida (strain
E. coli
M. marinus
P. somniferum
S. cerevisiae
T. equinum
S. fredii USDA
P. somniferum)
S. cerevisiae
S. cerevisiae
P. somniferum
S. cerevisiae
P. somniferum
E. coli
P. somniferum
O. sativa subsp.
E. coli
Japonica
S. fredii USDA
P. putida (strain
M. palustris
M. jannaschii
O. sativa subsp.
E. coli
Japonica
M. marinus
In the second round of engineering/screening, a third enzyme was expressed in the S. cerevisiae strain expressing a P. somniferum TYDC, along with an S. cerevisiae DAHP synthase with a K229L amino acid substitution from the first round. In some cases, the nucleotide sequence encoding the third enzymes was codon-optimized. Table 2 shows the third enzymes tested and the resultant tyramine titers. The higher titer was about 346 mg/L, an almost 1000-fold improvement, which was achieved by the strain expressing native S. cerevisiae prephenate dehydrogenase as the third enzyme.
Escherichia coli
Saccharomyces cerevisiae
Escherichia coli
Saccharomyces cerevisiae
Saccharomyces cerevisiae
Saccharomyces cerevisiae
Saccharomyces cerevisiae
Saccharomyces cerevisiae
Saccharomyces cerevisiae
Saccharomyces cerevisiae
Saccharomyces cerevisiae
Saccharomyces cerevisiae
Saccharomyces cerevisiae
Saccharomyces cerevisiae
The best-performing strain of Example 1 was selected as the control strain to in which to test a third round of genetic engineering in an effort to improve tyramine in Saccharomyces cerevisiae (“Improvement Round”). The control strain expressed prephenate dehydrogenase from S. cerevisiae (UniProt ID P20049)(SEQ ID NO:4), DAHP synthase from S. cerevisiae S288c (UniProt ID P32449)(SEQ ID NO:6) harboring the amino acid substitution K229L and tyrosine/DOPA decarboxylase 2 from Papaver somniferum (UniProt ID P54769)(SEQ ID NO:2). Tyramine production was improved in S. cerevisiae for eight strains relative to the control, and of these strains the strain giving the highest titer (299 mg/L vs. 266 mg/L for the control) expressed transaldolase from S. cerevisiae (UniProt ID P15019)(SEQ ID NO:8).
Tyramine production was improved by expression of each of the following heterologous enzymes or combinations of heterologous enzymes relative to the control:
The results are shown in Table 7 (below) and
In further designs, production of tyramine can be tested for improvement in strains containing the addition of the following heterologous enzymes or combinations of heterologous enzymes to the best-performing strain from this Example:
Host evaluation designs were tested in Yarrowia lipolytica, Bacillus subtilus, S. cerevisiae and Corynebacteria glutamicum. Tyramine production was demonstrated in all strains tested. The best-performing Y. lipolytica strain on average produced 54.5 mg/L tyramine. The best-performing B. subtilus strain produced 19.9 mg/L tyramine. The best-performing S. cerevisiae strain from the host evaluation produced 189 mg/L tyramine. The best-performing C. glutamicum strain produced 467 mg/L tyramine.
The best performing Y. lipolytica strain on average produced 54.5 mg/L tyramine and expressed the pyridoxal-dependent decarboxylase (TYDC) from Enterococcus faecium Com15 (UniProt ID C9ASN2) (SEQ ID NO:1), phospho-2-dehydro-3-deoxyheptonate aldolase (DAHP synthase) from S. cerevisiae S288c (UniProt ID P32449) (SEQ ID NO:9), where the DNA sequences for both enzymes were codon-optimized for Y. lipolytica. (Table 3,
The best-performing B. subtilis strain produced 19.9 mg/L tyramine and expressed the tyrosine/DOPA decarboxylase 2 (TYDC) from Papaver somniferum (SEQ ID NO:2), phospho-2-dehydro-3-deoxyheptonate aldolase (DAHP synthase) from Saccharomyces cerevisiae S288c (UniProt ID P32449) (SEQ ID NO: 9), and shikimate kinase 2 from Escherichia coli K12 (UniProt ID P0A6E1) (SEQ ID NO: 15), where the DNA sequences for all three enzymes were codon-optimized for S. cerevisiae. (Table 4,
The best-performing S. cerevisiae strain from the host evaluation produced 189 mg/L tyramine and expressed pyridoxal-dependent decarboxylase (TYDC) from E. faecium Com15 (UniProt ID C9ASN2) (SEQ ID NO:1), phospho-2-dehydro-3-deoxyheptonate aldolase (DAHP synthase) from S. cerevisiae S288c (UniProt ID P32449) harboring the amino acid substitution K229L (SEQ ID NO:6), where the DNA sequences for both enzymes were codon-optimized using a modified combined codon table for C. glutamicum and S. cerevisiae. (Table 5,
The best-performing C. glutamicum strain produced 467 mg/L tyramine and expressed pyridoxal-dependent decarboxylase (TYDC) from E. faecium Com15 (UniProt ID C9ASN2) (SEQ ID NO:1), phospho-2-dehydro-3-deoxyheptonate aldolase from (DAHP synthase) S. cerevisiae S288c (UniProt ID P32449) (SEQ ID NO:9), where the DNA sequences for both enzymes was codon-optimized for S. cerevisiae. (Table 6,
To improve a platform C. glutamicum strain for production of stilbenes and (2S)-flavanones Kallscheuer et al. (see References below) deleted genes and operons that degrade aromatic rings including polypropanoid degradation operon (phdBCDE, cg0344-47); 4-hydroxybenzoate-3-hydrolase (pobA (cg1226); the gene cluster harboring cat, ben, pca (cg2625-40), which is essential for degradation of 4-hydroxybenzoate, catechol, benzoate, and protocatechuate; and qsuE (cg0502), which is part of an operon comprised of essential genes of the anabolic shikimate pathway. Production of tyramine in C. glutamicum can also be tested for further improvement by deleting or lowering expression of these enzymes which degrade aromatics, since tyramine contains an aromatic ring.
Papaver
somniferum
Papaver
somniferum
Papaver
somniferum
Papaver
somniferum
Entero-
coccus
faecium
Entero-
coccus
faecium
Entero-
coccus
faecium
Entero-
coccus
faecium
Papaver
somniferum
Papaver
somniferum
Papaver
somniferum
S. cerevisiae
S. cerevisiae
S. cerevisiae
S. cerevisiae
S. cerevisiae
S. cerevisiae
S. cerevisiae
S. cerevisiae
S. cerevisiae
Escherichia
coli K12
S. cerevisiae
Escherichia
coli K12
S. cerevisiae
Escherichia
coli K12
Papaver
somniferum
Entero-
coccus
faecium
Papaver
somniferum
Papaver
somniferum
Papaver
somniferum
Entero-
coccus
faecium
Entero-
coccus
faecium
Entero-
coccus
faecium
Papaver
somniferum
Papaver
somniferum
Papaver
somniferum
Papaver
somniferum
Papaver
somniferum
S. cerevisiae
S. cerevisiae
S. cerevisiae
S. cerevisiae
S. cerevisiae
S. cerevisiae
S. cerevisiae
S. cerevisiae
S. cerevisiae
Escherichia
coli (strain
S. cerevisiae
Escherichia
coli (strain
S. cerevisiae
Escherichia
coli (strain
S. cerevisiae
Escherichia
coli (strain
S. cerevisiae
Saccharomyces
cerevisiae
Papaver
somniferum
Papaver
somniferum
Papaver
somniferum
Papaver
somniferum
Papaver
somniferum
Papaver
somniferum
Papaver
somniferum
S. cerevisiae
S. cerevisiae
S. cerevisiae
S. cerevisiae
S. cerevisiae
Escherichia
coli (strain
S. cerevisiae
Escherichia
coli (strain
S. cerevisiae
Escherichia
coli (strain
Papaver
somniferum
Papaver
somniferum
Papaver
somniferum
Papaver
somniferum
Entero-
coccus
faecium
Entero-
coccus
faceium
Entero-
coccus
faecium
Papaver
somniferum
Papaver
somniferum
Papaver
somniferum
S. cerevisiae
S. cerevisiae
S. cerevisiae
S. cerevisiae
S. cerevisiae
S. cerevisiae
S. cerevisiae
S. cerevisiae
Escherichia
coli (strain
S. cerevisiae
Escherichia
coli (strain
S. cerevisiae
Escherichia
coli (strain
Pyrococcus
furiosus ATCC
Meyerozyma
guilliermondii
Escherichia
coli K12
Escherichia
coli K12
Escherichia
coli K12
Dickeya
chrysanthemi
S. cerevisiae
Escherichia
coli K12
Escherichia
coli K12
S. cerevisiae
S. cerevisiae
S. cerevisiae
Homo sapiens
S. cerevisiae
Escherichia
coli K12
Escherichia
coli K12
S. cerevisiae
S. cerevisiae
S. cerevisiae
S. cerevisiae
S. cerevisiae
S. cerevisiae
S. cerevisiae
S. cerevisiae
S. cerevisiae
Clostridium
acetobutylicum
Arabidopsis
thaliana
Chlamy-
domonas
reinhardtii
Staphylo-
coccus
epidermidis
Gracilaria
gracilis (Red
Escherichia
coli K12
S cerevisiae
S cerevisiae
S cerevisiae
Escherichia
coli K12
Escherichia
coli K12
Escherichia
coli K12
Helicobacter
pylori ATCC
Aero-
pyrum pernix
Escherichia
coli (strain
Escherichia
coli (strain
S. cerevisiae
S. cerevisiae
Escherichia
coli (strain
S. cerevisiae
S. cerevisiae
E. coli
S. cerevisiae
E. coli
Escherichia
coli K12
S. cerevisiae
S. cerevisiae
E. coli
S.
E. coli
cerevisiae
S. cerevisiae
E. coli
Enterococcus faecium Com15
Papaver somniferum (Opium poppy)
S cerevisiae
Saccharomyces cerevisiae (strain
Saccharomyces cerevisiae (strain
Saccharomyces cerevisiae (strain
Escherichia coli (strain K12)
Saccharomyces cerevisiae (strain
Saccharomyces cerevisiae (strain
Saccharomyces cerevisiae (strain
Yarrowia lipolytica
Zygosaccharomyces bailii
S cerevisiae
Saccharomyces cerevisiae S288c
glutamicum and
Saccharomyces
cerevisiae
Escherichia coli (strain K12)
Bacillus subtillus
Escherichia coli (strain K12)
Methanosphaerula palustris (strain
Propionibacterium sp. oral taxon 192
Petroselinum crispum
Trichophyton equinum (strain ATCC
Streptomyces sviceus ATCC 29083
Pseudomonas putida (strain KT2440)
Modestobacter marinus (strain BC501)
Sinorhizobium fredii USDA 257
Oryza sativa subsp. Japonica
Methanocaldococcus jannaschii
Saccharomyces cerevisiae (strain
Saccharomyces cerevisiae(strain
Saccharomyces cerevisiae (strain
Escherichia coli (strain K12)
Saccharomyces cerevisiae (strain
Gracilaria gracilis (Red alga)
Pyrococcus furiosus (strain ATCC
Meyerozyma guilliermondii (strain
Escherichia coli (strain K12)
Saccharomyces cerevisiae (strain
Homo sapiens (Human)
Escherichia coli (strain K12)
Escherichia coli (strain K12)
Saccharomyces cerevisiae (strain
Enterococcus faecium Com15
Yarrowia lipolytica
Escherichia coli (strain K12)
Saccharomyces
cerevisiae
Saccharomyces cerevisiae (strain
Saccharomyces
cerevisiae
Enterococcus faecium Com15
Saccharomyces
cerevisiae
Saccharomyces cerevisiae (strain
glutamicum and
Saccharomyces
cerevisiae
Enterococcus faecium Com15
glutamicum and
Saccharomyces
cerevisiae
Escherichia coli (strain K12)
Escherichia coli (strain K12)
Dickeya chrysanthemi
Clostridium acetobutylicum (strain
Arabidopsis thaliana (Mouse-ear
Chlamydomonas reinhardtii
Staphylococcus epidermidis (strain
Escherichia coli (strain K12)
Helicobacter pylori (strain J99/ATCC
Aeropyrum pernix (strain ATCC
Escherichia coli (strain K12)
Papaver somniferum (Opium poppy)
Bacillus subtillus
Saccharomyces cerevisiae (strain
Bacillus subtillus
Papaver somniferum (Opium poppy)
glutamicum and
Saccharomyces
cerevisiae
Papaver somniferum (Opium poppy)
Saccharomyces
cerevisiae
Saccharomyces cerevisiae (strain
Saccharomyces
cerevisiae
Papaver somniferum (Opium poppy)
Yarrowia lipolytica
Saccharomyces cerevisiae (strain
Yarrowia lipolytica
Enterococcus faecium Com15
Bacillus subtillus
Saccharomyces cerevisiae (strain
Bacillus subtillus
Saccharomyces cerevisiae (strain
glutamicum and
Saccharomyces
cerevisiae
Escherichia coli (strain K12)
Yarrowia lipolytica
Escherichia coli (strain K12)
glutamicum and
Saccharomyces
cerevisiae
Papaver somniferum (Opium poppy)
glutamicum and
Saccharomyces
cerevisiae
Saccharomyces cerevisiae (strain
glutamicum and
Saccharomyces
cerevisiae
Saccharomyces cerevisiae (strain
glutamicum and
Saccharomyces
cerevisiae
Pyrococcus furiosus (strain ATCC
glutamicum and
Saccharomyces
cerevisiae
Escherichia coli (strain K12)
glutamicum and
Saccharomyces
cerevisiae
Meyerozyma guilliermondii (strain
glutamicum and
Saccharomyces
cerevisiae
Escherichia coli (strain K12)
glutamicum and
Saccharomyces
cerevisiae
Escherichia coli (strain K12)
glutamicum and
Saccharomyces
cerevisiae
Saccharomyces cerevisiae (strain
glutamicum and
Saccharomyces
cerevisiae
Escherichia coli (strain K12)
glutamicum and
Saccharomyces
cerevisiae
Escherichia coli (strain K12)
glutamicum and
Saccharomyces
cerevisiae
Dickeya chrysanthemi
glutamicum and
Saccharomyces
cerevisiae
Saccharomyces cerevisiae (strain
Corynebacterium
glutamicum codon
Saccharomyces cerevisiae (strain
glutamicum and
Saccharomyces
cerevisiae
Escherichia coli (strain K12)
glutamicum and
Saccharomyces
Saccharomyces cerevisiae (strain
glutamicum and
Saccharomyces
cerevisiae
Homo sapiens (Human)
glutamicum and
Saccharomyces
cerevisiae
Saccharomyces cerevisiae (strain
glutamicum and
Saccharomyces
cerevisiae
Saccharomyces cerevisiae (strain
glutamicum and
Saccharomyces
cerevisiae
Clostridium acetobutylicum (strain
glutamicum and
Saccharomyces
cerevisiae
Arabidopsis thaliana (Mouse-ear
glutamicum and
Saccharomyces
cerevisiae
Chlamydomonas reinhardtii
glutamicum and
Saccharomyces
cerevisiae
Staphylococcus epidermidis (strain
glutamicum and
Saccharomyces
cerevisiae
Gracilaria gracilis (Red alga)
glutamicum and
Saccharomyces
cerevisiae
Escherichia coli (strain K12)
glutamicum and
Saccharomyces
cerevisiae
Saccharomyces cerevisiae (strain
glutamicum and
Saccharomyces
cerevisiae
Saccharomyces cerevisiae (strain
glutamicum and
Saccharomyces
cerevisiae
Escherichia coli (strain K12)
glutamicum and
Saccharomyces
cerevisiae
Escherichia coli (strain K12)
glutamicum and
Saccharomyces
cerevisiae
Escherichia coli (strain K12)
glutamicum and
Saccharomyces
cerevisiae
Helicobacter pylori (strain J99/ATCC
glutamicum and
Saccharomyces
cerevisiae
Aeropyrum pernix (strain ATCC
glutamicum and
Saccharomyces
cerevisiae
Enterococcus faecium (Streptococcus
faecium)
Zygosaccharomyces bailii ISA 1307
Methanosphaerula palustris (strain
Propionibacterium sp. oral taxon 192
Petroselinum crispum
Trichophyton equinum (strain ATCC
Streptomyces sviceus ATCC 29083
Pseudomonas putida (strain KT2440)
Modestobacter marinus (strain BC501)
Papaver somniferum
Sinorhizobium fredii USDA 257
Papaver somniferum
Oryza sativa subsp. Japonica
Methanocaldococcus jannaschii
Saccharomyces cerevisiae
Escherichia coli
Escherichia coli
Saccharomyces cerevisiae CEN.PK2
Saccharomyces cerevisiae (strain
Saccharomyces cerevisiae (strain
Saccharomyces cerevisiae (strain
Saccharomyces cerevisiae (strain
This application is a continuation application of international application no. PCT/US2018/17127, filed Feb. 6, 2018, which claims the benefit of U.S. provisional application No. 62/455,428, filed Feb. 6, 2017, both of which are hereby incorporated by reference in their entireties.
This invention was made with Government support under Agreement No. HR0011-15-9-0014, awarded by DARPA. The Government has certain rights in the invention.
| Number | Name | Date | Kind |
|---|---|---|---|
| 4681852 | Tribe | Jul 1987 | A |
| 5756347 | Sugimoto et al. | May 1998 | A |
| 6210937 | Ward et al. | Apr 2001 | B1 |
| 7642083 | Frost et al. | Jan 2010 | B2 |
| 9234203 | Pang et al. | Jan 2016 | B2 |
| 9322039 | Smolke et al. | Apr 2016 | B2 |
| 20020009801 | Falco et al. | Jan 2002 | A1 |
| 20040091891 | Iomantas et al. | May 2004 | A1 |
| 20050089974 | Townsend et al. | Apr 2005 | A1 |
| 20080102499 | Templeton et al. | May 2008 | A1 |
| 20080118958 | Gatenby et al. | May 2008 | A1 |
| 20080176754 | Smolke et al. | Jul 2008 | A1 |
| 20090139134 | Yoshikuni et al. | Jun 2009 | A1 |
| 20110097767 | Pharkya et al. | Apr 2011 | A1 |
| 20140134689 | Lee et al. | May 2014 | A1 |
| 20150044755 | Yocum et al. | Feb 2015 | A1 |
| 20160251688 | Siddiqui et al. | Sep 2016 | A1 |
| 20170130250 | Facchini | May 2017 | A1 |
| 20180163241 | Smolke | Jun 2018 | A1 |
| Number | Date | Country |
|---|---|---|
| 0077196 | Apr 1983 | EP |
| 1187930 | Aug 2006 | EP |
| 2302067 | Mar 2014 | EP |
| 2147972 | Nov 2015 | EP |
| WO 96008567 | Mar 1996 | WO |
| WO 2008064835 | Jun 2008 | WO |
| WO 2015066642 | May 2015 | WO |
| WO 2015192233 | Dec 2015 | WO |
| WO 2016027870 | Feb 2016 | WO |
| WO 2018203947 | Nov 2018 | WO |
| Entry |
|---|
| F. Liu et al. “Heterologous Expression and Characterization of Tyrosine Decarboxylase from Enterococcus faecalis R612Z1 and Enterococcus faecium R615Z1”, Journal of Food Protection 77(4):592-598. (Year: 2014). |
| A. Rao et al. “Cloning and expression of a tyrosinase from Aspergillus oryzae in Yarrowia lipolytica: application in L-DOPA biotransformation”, Appl. Microbiol. Biotechnol. 92: 951-959. (Year: 2011). |
| PCT International Search Report and Written Opinion dated Dec. 20, 2018 issued in PCT/US2018/017127. |
| PCT International Preliminary Report on Patentability and Written Opinion dated Aug. 6, 2019 issued in PCT/US2018/017127. |
| Database Protein [Online] (Feb. 15, 2014) “probable tyrosine decarboxylase [Zygosaccharomyces bailii ISA1307]”, XP002786815, retrieved from NCBI Database accession No. CDH10044 (2 pages). |
| Database Protein [Online] (Jan. 16, 2015) “3-dehydroquinate synthase [Escherichia coli ]”, XP002786811, retrieved from GenBank accession No. KIH37536.1 (2 pages). |
| Database Protein [Online] (Apr. 22, 1996) “tyrosine decarboxylase [Papaver somniferum]”, XP0002786812, retrieved from GenBank accession No. AAA97535.1 (2 pages). |
| Database Protein [Online] (Sep. 25, 2013) “tyrosine decarboxylase [Enterococcus faecium]”, XP002786813, retrieved from GenBank accession No. AGW24520.1 (2 pages). |
| Database Protein [Online] (Jul. 26, 2016) “Lactobacillus brevis drug transport protein (dtp) gene, partial cds; acetyl coA synthetase (act), transposase (tra), tyrosyl-tRNA synthetase (tyrS), tyrosine decarboxylase (tyrdc), tyrosine permease(tyrP), Na+/H+ antiporter (nhaC), and ornithine transcarbamyl . . . ”, XP0002786814, retrieved from GenBank accession No. EU195891.1 (8 pages). |
| Database Protein [Online] (Nov. 30, 2016) “RecName: Full=Pentafunctional AROM polypeptide; Includes: RecName: Full=3-dehydroquinate synthase; Short=DHQS; Includes: RecName: Full=3-phosphoshikimate1-carboxyvinyltransferase; AltName: Full=5-enolpyruvylshikimate-3-phosphate synthase; Short=EPSP synthase; . . . ”, XP002786810, retrieved from UniProt accession No. P08566 (11 pages). |
| Dewick et al. (1993) “The Biosynthesis of Shikimate Metabolites”, Natural Product Reports, 10:233 (31 pages). |
| Gold et al. (2015) “Metabolic engineering of a tyrosine-overproducing yeast platform using targeted metabolomics”, Microbial Cell Factories, 14:73 (16 pages). |
| Hawkins, Kristy (2009) “Metabolic Engineering of Saccharomyces cerevisiae for the Production of Benzylisoquinoline Alkaloids” California Institute of Technology, Pasadena, California, 168 pages. |
| Ikeda (2006) “Towards bacterial strains overproducing L-tryptophan and other aromatics by metabolic engineering”, Appl Microbiol Biotechnol, 69: 615-626. |
| Jossek et al. (2001) “Characterization of a new feedback-resistant 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase AroF of Escherichia coli”, FEMS Microbiol Lett, 202: 145-148. |
| Koma et al. (2012) “A convenient method for multiple insertions of desired genes into target loci on the Escherichia coli chromosome”, Appl Microbiol Biotechnol, 93:815-829. |
| Koma et al. (2012) “Production of Aromatic Compounds by Metabolically Engineered Escherichia coli with an Expanded Shikimate Pathway”, Applied and Environmental Microbiology, 78(17):6203-6216. |
| Liao et al. (2001) “Serine 187 is a crucial residue for allosteric regulation of Corynebacterium glutamicum 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase”, FEMS Microbiol Lett, 194: 59-64. |
| Liu et al. (2008) “Corynebacterium glutamicum Contains 3-Deoxy-D-Arabino-Heptulosonate 7-Phosphate Synthases That Display Novel Biochemical Features”, Applied and Environmental Microbiology, 74(17): 5497-5503. |
| Meuris et al. (1974) “Feedback-Insensitive Mutants of the Gene for the Tyrosine-Inhibited Dahp* Synthetase in Yeast”, Genetics, 16: 735-744. |
| Noda et al. (2015) “Evaluation of Brachypodium distachyon L-Tyrosine Decarboxylase Using L-Tyrosine Over-Producing Saccharomyces cerevisiae”, PLOS ONE, 10(5): E0125488 (12 pages). |
| Romboli et al. (2015) “Effect of Saccharomyces cerevisiae and Candida zemplinina on quercetin, vitisin A and hydroxytyrosol contents in Sangiovese wines”, World J Microbiol Biotechnol, 31:1137-1145. |
| Webby et al. (2005) “Characterization of a recombinant type II 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase from Helicobacter pylori”, Biochem. J., 390: 223-230. |
| Zhang et al. (2014) “Construction and application of novel feedback-resistant 3-deoxy-D-arabino-heptulosonate-7-phosphate synthases by engineering the N-terminal domain for L-phenylalanine synthesis”, FEMS Microbiol Lett, 353: 11-18. |
| Zhang et al. (2016) “Three-step biocatalytic reaction using whole cells for efficient production of tyramine from keratin acid hydrolysis wastewater”, Appl Microbiol Biotechnol, 100: 1691-1700. |
| Number | Date | Country | |
|---|---|---|---|
| 20190390236 A1 | Dec 2019 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62455428 | Feb 2017 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | PCT/US2018/017127 | Feb 2018 | US |
| Child | 16453648 | US |
